A more careful look at silence as a possible signal, not proof
There’s a question that follows logically from everything in this series about InspireMD (NSPR). You’ve read about the clinical data. The job postings. The strategic logic. The catalyst calendar. The architects. The syndicate of 48 institutions. And at the end of all of that, one question remains: if all of this is true, why is the stock at $1.65?
It’s a fair question. And it deserves a serious answer.
⚠️ Reader notice: The author holds a position or has active interest in NSPR at the time of writing. Nothing in this article constitutes financial advice. All analysis is based on publicly available information. Do your own due diligence.
The standard explanations don’t hold up. It’s not that the market hasn’t had the information. The earnings reports are public. The job postings are public. The board appointments are public. The 13F filings are public. The clinical data is published in the Journal of the American College of Cardiology.
So what explains $1.65?
I think the answer may be simpler, and more structural, than most people expect. In some situations, the people with the most influence over a stock may have limited incentive to actively promote it.
The Conventional Assumption, And Why It May Not Apply Here
Most investors assume that management teams of public companies have a strong, consistent incentive to promote their stock. Investor days. Roadshows. Aggressive guidance. The entire apparatus of investor relations exists, in theory, to close the gap between a company’s intrinsic value and its market price.
That assumption is usually correct. But it rests on a specific underlying condition: that a higher stock price today is unambiguously better for the people making the decisions.
Remove that condition, and the incentive to promote disappears entirely.
Circumstance 1: One Plausible Explanation; A More Strategic Incentive Structure
This is the most important circumstance, and the most speculative, so I want to be precise about what I am and am not claiming. I am not claiming that a transaction is currently being negotiated. I have no non-public information.
What I am claiming is narrower: the incentive structure is at least compatible with a strategic-option mindset, and that may explain some of the silence better than the default assumption that everyone wants a higher stock immediately.
From a strategic buyer's perspective:
A stock at $1.65 can be acquired at $10-15 with a premium that every shareholder celebrates
A stock at $5.00 requires a deal at $12-18 to generate the same enthusiasm.
The absolute dollar cost increases by hundreds of millions.
From the institutional investors' perspective:
OrbiMed and Marshall Wace entered at $2.42
If the deal is announced at $12-15, they make 5-6x their investment regardless of what the stock does before announcement.
From management's perspective:
Slosman holds 3.5 million shares
At $1.65: worth approximately $5.8 million
At $12 in a deal: worth $42 million
⚠️ These figures are illustrative of incentive structure, not forecasts of any transaction terms. These are interpretive frameworks, not price targets. The market may respond differently to any outcome depending on context, guidance revisions, and broader conditions.
None of this requires conspiracy. It requires only that rational actors pursue their own interests, which is the most reliable assumption in finance.
Circumstance 2: The Milestone Financing
InspireMD has two remaining tranches of $17.9 million each from the 2023 private placement, tied to specific milestones.
If the stock is still depressed when TCAR is approved and the milestone tranche gets exercised, the economics of that step look different than they would from a much higher base.
No conspiracy required. Just rational actors with specific financial interests around specific events.
Circumstance 3: Management Equity Incentives
InspireMD’s management team receives a significant portion of their compensation in equity, RSUs and options granted periodically by the board.
Options granted when the stock is at $1.65 create obvious leverage to future upside. That does not mean management is suppressing the stock; it simply means the timing of equity grants and re-ratings is not economically neutral.
This is not unique to InspireMD. It is a structural feature of equity compensation at every public company.
Circumstance 4: The Post-PIPE Lock-Up Dynamics
With average daily volume of approximately 25,000 shares, OrbiMed and Marshall Wace cannot exit their positions without either accepting significant price impact or waiting for a liquidity event that provides an orderly exit.
Their incentive may be less about promotion and more about waiting for a cleaner liquidity event, broader validation, or a sharper re-pricing driven by milestones rather than commentary.
What The Silence Sounds Like In Practice
On March 18, 2026, InspireMD reported fourth quarter results showing 62% year-over-year revenue growth, 74% sequential US revenue growth, and provided 2026 guidance of $13-15 million. The stock went down.
There are several explanations. One is that the market simply hasn’t processed the information yet. Another is that many of the investors best positioned to understand it are already in, which reduces the urgency to create incremental buying pressure at today’s price.
I cannot tell you which explanation is dominant. What I can say is that the second explanation is at least consistent with the incentive structure around the stock.
The Analyst Who Asked The Question Nobody Else Did
On the March 18th earnings call, an analyst from Piper Sandler asked management about the integration of CGuard Prime with the Boston Scientific Silk Road system. At the same time, none of the three analysts on that call asked about the COO departure that had been announced three weeks earlier.
One analyst asked about Boston Scientific integration No analyst asked about the COO departure
That could mean the market’s attention is already shifting toward strategic direction rather than the administrative details of who left.
It could also mean nothing more than limited Q&A time. The point is not certainty, the point is where the attention went.
What I’m Not Saying
I want to be precise about the limits of this argument. I am not saying a transaction is occurring. I don’t know that. I am not saying the silence is proof of anything.
What I am saying is this: the incentive structure of every major party involved in InspireMD, management, institutional investors, board members, is at least consistent with a situation where actively promoting the stock before key future events is not the only rational priority.
That is a verifiable observation about incentives. Not a claim about facts I cannot know.
And when you combine that observation with everything else in this series, the clinical data, the job postings, the strategic logic, the catalyst calendar, the architects, the syndicate, the silence becomes more interpretable, even if it remains inconclusive.
To me, it is not proof. It is one more piece of context.
Next in the series: ‘InspireMD (NSPR): Reading The Silence’, the final piece of the series, and the limits of the thesis.
🟢 Disclosure: The author holds a position or has active interest in this name.
⚠️ I produce these analyses for my own enjoyment and because I’m always looking for new opportunities. I am not a financial professional, and I don’t have access to professional-grade tools or proprietary data. Everything here is built from publicly available information and my own reasoning — which means I can be wrong. I may not always see the full picture, and my views will change as new information emerges or as I come to understand data points I initially overlooked or underweighted. I only operate with cash positions — no leverage, no margin, no shorting. I never bet against the market or individual companies. My analysis reflects the company’s fundamentals, not its price action. The company is not its price, and the price is not the company. I express my own opinions. I am not receiving compensation to share this. I have no business relationship with any company whose stock is mentioned in this